Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Imports Could Be "Good For The Country," Caremark Suggests

This article was originally published in The Pink Sheet Daily

Executive Summary

Caremark sees the potential for legalized wholesale imports from Canada to offer an opportunity analogous to the current profit and savings impact of generic drugs

You may also be interested in...

Canadian Rx Imports Would Supply 10% Of U.S. Market, Caremark Exec Says

The limited supply of drugs coming from Canada under a legalized importation system would have little impact on U.S. prices, Caremark CEO Crawford says at PCMA annual meeting. Importation would require PBMs to decide how to distribute lower-priced Canadian products among their clients, he says.

‘March In’ Plan Unveiled By Democratic Think Tank: A Battle Biopharma Would Welcome?

In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts